On February 18, 2020 Horizon Therapeutics plc (Nasdaq: HZNP) reported that the Company will participate in the following conference in March (Press release, Horizon Therapeutics, FEB 18, 2020, https://ir.horizontherapeutics.com/news-releases/news-release-details/horizon-therapeutics-plc-present-cowen-and-company-40th-annual [SID1234554443]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cowen and Company 40th Annual Health Care Conference

Date: Tuesday, Mar. 3, 2020
Presentation Time: 12 p.m. ET
Location: Boston
The conference presentation will be webcast live and may be accessed by visiting Horizon’s website at View Source A replay of the webcast will be available for the event.

On February 18, 2020 Guided Therapeutics, Inc. (Pink Sheets: GTHP), the maker of a rapid and painless cervical cancer detection test based on its patented biophotonic technology, reported it had achieved significant progress with the U.S. FDA in restarting its efforts for sales and marketing approval of its LuViva Advanced Cervical Scan (Press release, Guided Therapeutics, FEB 18, 2020, View Source [SID1234554459]). After a succession of conference calls, emails and letters exchanged with FDA over the past 30 days, the Company was encouraged by the agency to file a Pre-submission document detailing its approach for a new clinical trial to support U.S. approval. The Company filed Pre-Submission document with FDA on February 17, 2020. The Pre-submission document is designed to elicit comment from FDA regarding the clinical trial so that a study protocol can be completed and the clinical trial started.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We have been pleased by FDA’s rapid responses to our plan for moving ahead with the approval process, which has allowed us to complete the initial phases of the study design ahead of schedule," said Gene Cartwright, CEO. "If our plan is accepted by FDA, we expect to complete and file the study protocol for comment within about 30 to 60 days, depending on how rapidly FDA responds to our recently filed Pre-submission document."

On February 18, 2020 Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, reported that its President and Chief Executive Officer, Peter L. Hoang, will present at two upcoming investor conferences (Press release, Marker Therapeutics, FEB 18, 2020, View Source [SID1234554475]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Details

Cowen 40th Annual Health Care Conference
Date: Wednesday, March 4, 2020
Time: 8:40 a.m. ET
Location: Boston, MA

Oppenheimer 30th Annual Healthcare Conference
Date: Wednesday, March 18, 2020
Time: 1:35 p.m. ET
Location: New York, NY

Live webcasts of the presentations will be accessible from the investors section of the company’s website at markertherapeutics.com and will be available for replay following the event.

On February 18, 2020 Epizyme, Inc. (Nasdaq: EPZM), a biopharmaceutical company developing novel epigenetic therapies, reported that management will host a conference call and webcast to discuss its fourth quarter and full year 2019 financial results and present at upcoming investor conferences (Press release, Epizyme, FEB 18, 2020, View Source [SID1234554444]). Details of the events are below:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Fourth Quarter and Full-Year 2019 Financial Results: Management will host a conference call and webcast to discuss its fourth quarter and full year 2019 financial results on Monday, Feb. 24, 2020 at 8:30 a.m. ET. To participate in the conference call, please dial (877) 844-6886 (domestic) or (970) 315-0315 (international) and refer to conference ID 9045277.

Upcoming Investor Conference Presentations: Management will present at the following upcoming conferences:
9th Annual SVB Leerink Global Healthcare Conference on Tuesday, Feb. 25, 2020 at 1:00 p.m. ET in New York City;
Cowen and Company’s 40th Annual Healthcare Conference on Monday, March 2, 2020 at 3:30 p.m. ET in Boston;
Barclays Global Healthcare Conference on Tuesday, March 10, 2020 at 2:05 p.m. ET in Miami; and,
Oppenheimer 30th Annual Healthcare Conference on Tuesday, March 17, 2020 at 3:55 p.m. ET in New York City.
Live webcasts will be available in the investor section of the company’s website at www.epizyme.com. The webcasts will be archived for 60 days following the call and presentations.

On February 18, 2020 Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) reported it will release results for the fourth quarter and full year 2019 on Tuesday, February 25, 2020, after the market closes (Press release, Vanda Pharmaceuticals, FEB 18, 2020, View Source [SID1234554460]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Vanda will host a conference call at 4:30 PM ET on Tuesday, February 25, 2020, during which management will discuss the fourth quarter and full year 2019 financial results and other corporate activities. To participate in the conference call, please dial 1-866-688-9426 (domestic) or 1-409-216-0816 (international) and use passcode 2149683.

The conference call will be broadcast simultaneously and archived on Vanda’s website, www.vandapharma.com. Investors should go to the website at least 15 minutes early to register, download, and install any necessary audio software.

A replay of the call will be available on Tuesday, February 25, 2020, beginning at 7:30 PM ET and will be accessible until Tuesday, March 3, 2020, at 7:30 PM ET. The replay call-in number is 1-855-859-2056 for domestic callers and 1-404-537-3406 for international callers. The passcode number is 2149683.